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Abstract
Objective—US Hispanics/Latinos have high prevalence of obesity and related comorbidities. We 
compared overall and central obesity measures in associations with cardiometabolic outcomes 
among US Hispanics/Latinos.
Methods—Multivariable regression assessed cross-sectional relationships of six obesity 
measures with cardiometabolic outcomes among 16,415 Hispanics/Latinos aged 18-74 years.
Results—BMI was moderately correlated with waist-to-hip ratio (WHR; women, r=0.37; men, 
r=0.58) and highly correlated with other obesity measures (r≥0.87) (P<0.0001). All measures of 
obesity were correlated with unfavorable levels of glycemic traits, blood pressure, and lipids, with 
similar r-estimates for each obesity measure (P<0.05). Multivariable-adjusted prevalence ratios 
(PRs) for diabetes (women, 6.7 [3.9, 11.5]; men, 3.9 [2.2, 6.9]), hypertension (women, 2.4 [1.9, 
3.1]; men, 2.5 [1.9, 3.4]), and dyslipidemia (women, 2.1 [1.8, 2.4]; men, 2.2 [1.9, 2.6]) were 
highest for individuals characterized as overweight/obese (BMI≥25kg/m2) and abnormal WHR 
(women, ≥0.85; men, ≥0.90), compared to those with normal BMI and WHR (P<0.0001). Among 
normal-weight individuals, abnormal WHR was associated with increased cardiometabolic 
condition prevalence (P<0.05), particularly diabetes (women, PR=4.0 [2.2, 7.1]; men, PR=3.0 [1.6, 
5.7]).
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Conclusions—Obesity measures were associated with cardiometabolic risk factors to a similar 
degree in US Hispanics/Latinos. WHR is useful to identify individuals with normal BMI at 
increased cardiometabolic risk.
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Introduction
Obesity has become a major public health problem in the US, where over 35% of adults are 
obese (1). In particular, US Hispanics/Latinos, who are the fastest growing and largest 
minority group in the US, are disproportionately affected by obesity and related chronic 
diseases (1, 2). Recent data from the baseline examination of the Hispanic Community 
Health Study/Study of Latinos (HCHS/SOL), a population-based cohort of US Hispanics/
Latinos conducted between 2008 and 2011, estimated that 37% of men and 43% of women 
are obese (body mass index [BMI] ≥30 kg/m2) (3), with high prevalence of diabetes and 
metabolic syndrome as well (4, 5).
BMI has been the most widely used measure to describe overall obesity in epidemiological 
studies, but this index fails to distinguish body composition and to indicate body fat 
distribution. Alternatively, waist circumference (WC), waist-to-hip ratio (WHR), and waist-
to-height ratio (WHtR), which describe body fat distribution, have been used to measure 
central obesity. Although it has been demonstrated that each of these commonly used 
measures of obesity is associated with diabetes, hypertension, dyslipidemia and 
cardiovascular diseases (CVD) (6, 7, 8), controversy remains about the superiority of any 
one measure over others. Another approach to measuring body fat is bioelectrical impedance 
analysis, which is an efficient and safe method for field epidemiologic studies. (9, 10, 11) 
Accordingly, percent body fat (%BF) and fat mass index (FMI) have been also used as 
indices of obesity (11, 12, 13, 14).
Several studies have compared BMI, WC, and WHR in their associations with 
cardiometabolic outcomes in US Hispanics/Latinos and yielded various results (15, 16, 17, 
18, 19). For example, Zhu et al.(16) reported that WC might be a better indicator of 
cardiometabolic risk than BMI in 3 racial/ethnic groups including Mexican Americans, 
while Ghandehari et al. (17) suggested that BMI might be a better marker of cardiometabolic 
risk than WC in US Hispanics. In addition, another study found that measures of overall and 
central obesity were similar in predicting diabetes in a multi-ethnic cohort that included 
Hispanics (18). These inconsistent findings might be due to relatively small sample size of 
US Hispanic/Latino participants. In addition, previous studies included mostly Mexican 
Americans and body fat-related measures (%BF, FMI) have not been well-studied in 
populations of US Hispanics/Latinos. Moreover, it remains unclear whether BMI and other 
obesity measures assessed in combination could provide additional information in the 
identification of Hispanics/Latinos at increased cardiometabolic risk. Because of high 
correlations between obesity measures, large studies are needed to cross-classify individuals 
by more than one obesity measure. Therefore,in the current study, we aimed to evaluate six 
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obesity measures (BMI, WC, WHR, WHtR, %BF, and FMI) and their associations with 
major cardiometabolic diseases, including diabetes, hypertension, and dyslipidemia, as well 
as several cardiometabolic traits (glycemic traits, blood pressure, and blood lipids) among 
9835 women and 6580 men of diverse Hispanic backgrounds from the HCHS/SOL. 
Furthermore, we also examined cardiometabolic diseases and related traits according to 
normal and abnormal categories of obesity measures.
Methods
Participants
The HCHS/SOL is a population-based cohort study of Hispanic/Latino adults aged 18-74 
years living in 4 U.S. urban centers (Bronx, NY; Chicago, IL; Miami, FL; and San Diego, 
CA). The goal of HCHS/SOL is to determine the role of acculturation in the prevalence and 
development of disease, and to identify disease risk factors of importance in Hispanic/Latino 
communities. Participants were recruited using a 2-stage area probability sampling design as 
described in detail previously (20, 21). Of 39,384 individuals who met eligibility criteria, 
41.7% were enrolled, representing 16,415 persons from 9,872 households. Baseline 
interviews were conducted in English or Spanish at in-person clinic visits during 2008-2011. 
The study was approved by the Institutional Review Boards at each field center, and all 
participants gave written informed consent.
Obesity measures
Measurements of weight, %BF, and fat mass were obtained from the Tanita body 
composition analyzer (model TBF-300A; Tanita Corporation, Arlington Heights, IL). Height 
and waist and hip circumference were measured to the nearest centimeter based on a 
standard protocol (www.cscc.unc.edu/hchs). Body weight was measured to the nearest 0.1 
kg. BMI was calculated as weight in kilograms divided by height in meters squared. FMI 
was calculated as fat mass in kilograms divided by height in meters squared. Participants 
with a BMI 18.5-25.0 kg/m2 were defined as having a normal weight (normal BMI) and 
those with a BMI≥25 kg/m2 were defined as being overweight/obese (abnormal BMI). WC, 
WHR and %BF were dichotomized based on standard cutoffs for women (high WC, ≥80 
cm; high WHR, ≥0.85; high %BF, ≥30%) and men (high WC, ≥90 cm; high WHR, ≥0.90; 
high %BF, ≥25%) (14).
Cardiometabolic risk factors
After a 5-minute rest period, 3 seated blood pressure measurements were obtained with an 
automatic sphygmomanometer; the second and third readings were averaged. Blood samples 
(fasting and after a 2-hour oral glucose load) were collected and processed according to 
standardized protocols (www.cscc.unc.edu/hchs). Total serum cholesterol was measured 
using a cholesterol oxidase enzymatic method and high-density lipoprotein (HDL) 
cholesterol with a direct magnesium/dextran sulfate method. Plasma glucose was measured 
using a hexokinase enzymatic method (Roche Diagnostics). Low-density lipoprotein (LDL) 
cholesterol was calculated using the Friedewald equation (22). Hemoglobin A1c (HbA1c) 
was measured using a Tosoh G7 Automated HPLC Analyzer (Tosoh Bioscience). Fasting 
insulin was measured using two commercial immunoassays (ELISA, Mercodia AB, 
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Uppsala, Sweden; and sandwich immunoassay on a Roche Elecsys 2010 Analyzer, Roche 
Diagnostics, Indianapolis, IN); early measures conducted with the Mercodia assay were 
calibrated, and values were equivalent to the Roche method. Homeostatic model assessment 
of insulin resistance (HOMA-IR) was computed the following equation: fasting glucose × 
fasting insulin / 405 (23).
Participants were instructed to bring all prescription and nonprescription medications taken 
in the past month. Hypertension was defined as systolic blood pressure (SBP) ≥140 mmHg, 
diastolic blood pressure (DBP) ≥90 mmHg, or antihypertensive medication use (24). 
Diabetes was defined according to the American Diabetes Association (ADA) as at least one 
of the following: fasting glucose ≥126 mg/dL, 2-hour-postload glucose ≥200 mg/dL, HbA1c 
≥6.5%, or antidiabetic medication use (25). Dyslipidemia was defined as at least one of the 
following: LDL-cholesterol ≥160 mg/dL, HDL-cholesterol <50 mg/dL for women and <40 
mg/dL for men, triglycerides ≥200 mg/dL, or taking lipid-lowering drugs (26).
Covariate assessment
Self-reported questionnaires were used to collect information on age, Hispanic/Latino 
background, place of birth/nativity (inside versus outside the US 50 states plus the District 
of Columbia), education level, health insurance status, medical history, annual household 
income, smoking status, alcohol consumption, and combined work, travel, and leisure 
physical activity. Total physical activity was assessed using the Global Physical Activity 
Questionnaire developed by the World Health Organization (http://www.who.int/chp/steps/
GPAQ/en/index.html).
Statistical analysis
In accordance with procedures standard to large population-based studies (27), all reported 
values were non-response adjusted, trimmed, and calibrated by age, sex, and Hispanic/
Latino background (national heritage) to the characteristics of each field center's target 
population from the 2010 Census. All analyses also account for cluster sampling and 
stratification in the sample selection. Although no HCHS/SOL participants were excluded 
from the entire analysis, several observations were excluded from variable-specific analyses 
due to incomplete data, or for the following reasons: plasma cardiometabolic markers treated 
as missing for those not fasting at least 8 hours (n=294); BMI, WHtR and FMI treated as 
missing for those not able to stand erect for height measurement (n=157); FMI and %BF 
treated as missing for those not meeting data quality control (n=188).
Correlations between obesity measures were assessed using weighted age-adjusted partial 
Pearson correlation coefficients. Weighted age-adjusted partial Pearson correlations were 
also computed between obesity measures and cardiometabolic markers among those not 
taking antidiabetic medications, antihypertensive medications, or lipid-lowering drugs (7060 
women and 4961 men). Triglycerides, fasting insulin and HOMA-IR were natural logarithm-
transformed before analysis. Means of cardiometabolic markers for the target population of 
Hispanics/Latinos in the 4 HCHS/SOL communities were calculated using survey linear 
regression weighted least square. To evaluate the associations of obesity measures with 
prevalent hypertension, diabetes, and dyslipidemia, prevalence ratios were derived from 
Qi et al. Page 4













survey Poisson regression models with robust variance estimation. Besides taking into 
account the survey design and survey weights, these analyses were adjusted for age, 
Hispanic/Latino background, field center, nativity, education level, health insurance status, 
annual household income, smoking, alcohol consumption, and physical activity. In addition, 
agreement of normal and abnormal categories of obesity measures was assessed by the 
Cohen's kappa statistic. Analyses were performed using SAS version 9.3 (SAS Institute, 
Cary, NC) and SUDAAN release 11.0.1 (RTI International, Research Triangle Park, NC).
Results
Participant characteristics
Sex-specific characteristics of the study population are shown in Table 1. The mean age was 
41.8 years in women and 40.3 years in men. The largest group was of Mexican background 
(38% of women; 36% of men), followed by those of Cuban (18% of women; 22% of men) 
and Puerto Rican (15% of women; 17% of men) backgrounds. Greater than 75% of women 
and men were overweight, 22% of women and men had hypertension, 16% of women and 
14% of men had diabetes, and 59% of women and 52% of men had dyslipidemia. Data on 
prevalence of overweight/obesity, hypertension, diabetes and dyslipidemia across study sites 
are shown in Table S1, and data on prevalence of these cardiometabolic outcomes have been 
previously published elsewhere (3, 4).
Correlations of obesity measures with cardiometabolic markers
As shown in Table 2, there were high correlations among all obesity measures (except 
WHR) in women (r≥0.78) and men (r≥0.84). WHR showed moderate correlations with BMI 
(r=0.34 in women; r=0.58 in men), %BF (r=0.34 in women; r=0.56 in men) and FMI (r=0.35 
in women; r=0.58 in men). All correlations among obesity measures were statistically 
significant (P < 0.0001).
All obesity measures were positively correlated with systolic blood pressure, diastolic blood 
pressure, LDL-cholesterol, triglycerides, fasting glucose, 2-hour glucose, fasting insulin, 
HOMA-IR and HbA1c, and inversely correlated with HDL-cholesterol (Table 2; all P < 
0.002). The correlation coefficients of different obesity measures with each cardiometabolic 
marker were generally similar, except for WHR which showed slightly weaker correlations 
with fasting insulin and HOMA-IR compared with other obesity measures.
Associations of obesity measures with diabetes, hypertension and dyslipidemia
All obesity measures were positively associated with prevalence of diabetes (PR=1.41 to 
1.54 in women and PR=1.37 to 1.53 in men per SD increment), hypertension (PR=1.17 to 
1.31 in women and PR=1.29 to 1.36 in men per SD increment) and dyslipidemia (PR=1.17 
to 1.20 in women and PR=1.21 to 1.26 in men per SD increment) in both women and men, 
after adjustment for age, demographic and socioeconomic variables, and lifestyle factors 
(Table 3; all P < 0.0001). The PRs for each cardiometabolic condition with 1 SD increment 
in most obesity measures were similar in both women and men.
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In addition, associations between obesity measures and cardiometabolic diseases were, in 
general, consistent across Hispanic/Latino background groups (Table S2 and Table S3). 
Effect estimates were qualitatively similar for all associations of interest, with a few 
nominally statistically significant tests for interaction (P for interaction < 0.05). Possible 
heterogeneity in associations was only observed for WHR and dyslipidemia, and WHtR and 
Hypertension in men, with a P for interaction < 0.01.
Agreement of normal and abnormal categories of obesity measures
Table 4 shows the agreement of normal and abnormal categories of BMI, WC, WHR and 
%BF in women and men. Among overweight/obese women defined by BMI criteria, 99% 
were classified as abnormal by WC criteria, 80% were classified as abnormal by WHR 
criteria, and 98% were classified as abnormal by %BF criteria. However, among normal 
weight women defined by BMI criteria, 60% were classified as abnormal by WC criteria, 
50% were classified as abnormal by WHR criteria, and 41% were classified as abnormal by 
%BF criteria. Among overweight/obese men defined by BMI criteria, 78% were classified as 
abnormal by WC criteria, 84% were classified as abnormal by WHR criteria, and 79% were 
classified as abnormal by %BF criteria. Among normal weight men defined by BMI criteria, 
a small proportion of individuals were classified as abnormal by WC criteria (7%) or %BF 
criteria (6%), but 40% were classified as abnormal by WHR criteria. Cohen's kappa statistic 
indicates that WC criteria (K=0.48 in women and 0.57 in men) and %BF criteria (K=0.65 in 
women and 0.59 in men) had moderate agreement with BMI criteria, and WHR criteria had 
fair-to-moderate agreement with BMI criteria (K=0.28 in women and 0.41 in men).
Cardiometabolic risk according to normal and abnormal categories of obesity measures
After adjustment for age, demographic and socioeconomic variables, and lifestyle factors, 
PRs for diabetes, hypertension, and dyslipidemia differed across subgroups classified by 
BMI and other obesity measures (Table 5). The PRs for cardiometabolic diseases were the 
highest among those with both abnormal BMI and another obesity measure. In both women 
and men, the highest PRs (95% CI) for diabetes (6.70 [3.91, 11.48] in women; 3.91 [2.22, 
6.88] in men), hypertension (2.40 [1.87, 3.07] in women; 2.52 [1.87, 3.40] in men), and 
dyslipidemia (2.10 [1.83, 2.41] in women; 2.22 [1.89, 2.61] in men) were observed among 
overweight/obese individuals with abnormal WHR. Notably, abnormal WHR was also 
significantly associated with increased PRs of all three cardiometabolic diseases in normal-
weight women and men, with a remarkably high PR of diabetes (3.99 [2.23, 7.41] in women; 
3.04 [1.63, 5.66] in men).
Consistently, individuals with both abnormal BMI and WHR had the most adverse 
cardiometabolic risk factor profile (Figure 1). Moreover, individuals with normal BMI and 
abnormal WHR had significantly higher levels of diastolic blood pressure (men only), LDL-
cholesterol (men only), triglycerides, 2-hour glucose, and fasting insulin (all P < 0.05), and 
lower levels of HDL cholesterol (P< 0.01) compared with those with both normal BMI and 
WHR. Individuals with abnormal BMI and normal WHR had significantly more adverse 
levels of most of these cardiometabolic makers compared with those with both normal BMI 
and WHR.
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Results according to normal and abnormal categories of BMI and WC or %BF are show 
Figures S1 and S2. Similarly, individuals with both abnormalities had the most adverse 
cardiometabolic risk factor profile (P < 0.0001), and those with one abnormality had a 
significantly more adverse cardiometabolic risk factor profile compared with those with both 
normal obesity measures (P < 0.05).
Discussion
In this population-based cohort of over 16,000 US Hispanic/Latino women and men, we 
found that different obesity measures, including BMI, WC, WHR, WHtR, %BF and FMI, 
were all significantly associated with higher prevalence of diabetes, hypertension and 
dyslipidemia, as well as unfavorable cardiometabolic markers. The magnitudes of 
associations of BMI with cardiometabolic risk factors were similar to those of central 
obesity measures (WC, WHR and WHtR) and direct measurements of body fat (%BF and 
FMI), with none of the obesity measures showing a particularly stronger association. 
However, the agreement of normal and abnormal categories of BMI and other obesity 
measures were moderate, and individuals with abnormalities of both BMI and another 
obesity measure had particularly high cardiometabolic risk.
In the present study of US Hispanics/Latinos, the obesity measure that was most strongly 
associated with different cardiometabolic risk factors varied across risk factors, and in 
instances where one obesity measure may have been superior to others the differences were 
small. Our data are, in general, consistent with previous results in Hispanic populations(15, 
16, 17, 18, 19) as well as in diverse ethnic groups (6). Several meta-analyses of cross-
sectional and prospective data have suggested broad similarities in the magnitudes of 
associations of different obesity measures with major cardiometabolic diseases 
(hypertension, diabetes and dyslipidemia) (28, 29, 30, 31, 32), although slight differences 
between BMI and central obesity measures in the associations with diabetes were observed 
(29, 30, 32).Taken together, our data and previous findings suggest general consistency in 
the magnitudes of associations of different obesity measures with cardiometabolic risk 
factors. Any possible differences that were suggested by our analyses comparing individual 
obesity metrics, moreover, are unlikely to be of practical relevance for the use of these 
measures in clinical settings. Thus, the most important question might be how to best 
identify subgroups of individuals with excessive cardiometabolic risk using a combination of 
obesity measures, rather than which obesity measure alone is a stronger or better indicator 
for major cardiometabolic risk factors.
Prior studies on different obesity measures and cardiometabolic risk factors conducted in the 
US Hispanics/Latinos have largely examined individuals of Mexican background (15, 16, 
17, 18, 19). With the diverse representation of Hispanics/Latinos in the HCHS/SOL, we 
were able to examine these associations across Hispanic/Latino backgrounds. In general, our 
data show consistent positive associations between different obesity measures and 
cardiometabolic risk factors across these background groups. We found little evidence of 
effect modification by Hispanic/Latino background, with a few nominally statistically 
significant tests for interaction. However, given the complexity of the biological and cultural 
diversity within the US Hispanics/Latinos, more studies are needed to investigate potential 
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differences in these associations across Hispanic/Latino backgrounds. It is not surprising that 
most overweight/obese (abnormal BMI) individuals were classified as abnormal WC or 
abnormal WHR, and individuals in this subgroup had the most adverse CVD risk factor 
profile. This is in line with a recent study suggesting that either BMI or WC could identify 
the same individuals at increased cardiometabolic risk associated with excess adiposity (33). 
However, interestingly, a large proportion of normal weight individuals were classified as 
abnormal WHR for both women (50%) and men (40%). Moreover, abnormal WHR were 
significantly associated with higher prevalences of all three major cardiometabolic diseases, 
particularly diabetes (adjusted PR=3.99 for women and 3.05 for men) among normal weight 
individuals, suggesting that WHR measurement is informative and facilitates the 
identification of a subgroup of normal weight people at increased risk for diabetes and other 
cardiometabolic diseases. WHR may also reflect a ratio of trunk/abdominal fat and leg fat 
deposits, and a number of studies have demonstrated that trunk/abdominal fat is unfavorably 
associated with cardiometabolic risk factors, whereas leg fat is favorably associated with 
cardiometabolic risk factors (34, 35, 36, 37, 38, 39). A previous large-scale analysis showed 
that BMI and central obesity measures, particular WHR, assessed in combination could 
improve CVD risk prediction, and it is not surprising that the improvement was modest 
when data on conventional CVD risk factors (blood pressure, blood lipids, and diabetes, 
which are major mediators of adiposity and CVD (40)) were included (8).
Another finding of our study is that more direct measures of overall adiposity, FMI and %BF 
did not show stronger associations with cardiometabolic risk factors than BMI. Indeed, BMI 
was very highly correlated with FMI (r=0.94) and %BF (r≥0.88), suggesting that they may 
serve as alternate proxy measures of overall obesity. However, we only observed moderate 
agreement between normal and abnormal categories of BMI and %BF. Greater than 41% of 
normal weight women had abnormal %BF (≥30%), and those women were more likely to 
have hypertension, diabetes, and dyslipidemia as well as adverse cardiometabolic traits. 
These findings indicate that %BF, measured by bioelectrical impedance analysis which is a 
feasible and efficient method in large epidemiological studies (9, 10), is useful to identify 
normal weight people with excess adiposity at high cardiometabolic risk.
To the best of our knowledge, this is the largest study to date to evaluate different obesity 
measures and their relationships with major cardiometabolic risk factors as well as multiple 
cardiometabolic biomarkers among US Hispanics/Latinos. Our study population is a 
representative sample of Hispanic/Latino individuals of diverse backgrounds in 4 US 
communities, and multiple covariates were adjusted in our analyses. Nevertheless, our 
findings are limited to the nature of cross-sectional data and hence a lack of data on incident 
CVD events. However, conventional CVD risk factors examined in the current study appear 
to largely explain the excess obesity-related CVD risk (40). In addition, we used cut-off 
values for abnormal obesity measures that were originally derived from non-Hispanic white 
populations, since insufficient data are available to derive cut-offs for Hispanic populations. 
Finally, although we have included multiple measures for overall and central obesity, our 
study lacked data on precise measurements of regional fat distribution measured by 
computed tomography or magnetic resonance imaging. However, these approaches are 
expensive and time-consuming, which may be impractical for large epidemiological studies.
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In conclusion, our study shows that overall and central obesity measures were all associated 
with diabetes and other cardiometabolic diseases, as well as adverse cardiometabolic traits, 
and they performed similarly in their magnitudes of associations with cardiometabolic risk 
factors in US Hispanic/Latino women and men. As increases in other obesity measures (such 
as WHR) are also associated with CVD risk factors regardless of body weight, BMI alone 
may be insufficient as the only obesity measure to indicate increased cardiometabolic risk, 
particularly in those with normal weight. BMI and other obesity measures assessed in 
combination are useful to identify individuals at increased cardiometabolic risk, particularly 
of diabetes risk, associated with excess adiposity.
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What is already known about this subject?
• Increased levels of adiposity are related to poor cardiometabolic biomarker 
profiles and adverse cardiovascular health outcomes.
• Several measures have been developed to improve the assessment of overall and 
central adiposity, and therefore inform interventions to reduce cardiovascular 
risk.
• U.S. Hispanics/Latinos are disproportionately affected by obesity and 
cardiovascular disease relative to their non-Hispanic White counterparts.
What does this study add?
• We show among a novel, population-based sample of 16,000 Hispanics/Latinos 
that several measures of obesity are highly correlated with one another, and are 
related to cardiovascular risk factors to a similar degree.
• Even among individuals of normal body weight, Hispanic/Latino men and 
women with waist-to-hip ratios above clinical thresholds are much more likely 
to have prevalent hypertension, adverse lipid profiles, and particularly diabetes.
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Mean (95% confidence interval) values of cardiometabolic biomarkers according to normal 
and abnormal categories of BMI and WHR.
Values are adjusted for age, sampling scheme of the Hispanic Community Health Study /
Study of Latinos (HCHS/SOL), Hispanic background, field center, nativity, education level, 
health insurance status, annual household income, smoking, alcohol consumption, and 
physical activity. Participants receiving medications for hypertension, diabetes, or 
dyslipidemia were excluded from the analysis for all cardiometabolic markers. Significant 
differences in means between the groups: **P<0.01 and *P<0.05 for comparison with the 
normal BMI and normal WHR group. Normal BMI: 18.5≤BMI<25 kg/m2; Abnormal BMI: 
BMI≥25 kg/m2. Normal WHR: <0.90 in men/<0.85 in women; Abnormal WHR: ≥0.9 in 
men/≥0.85 in women. BMI, body mass index; WHR, waist-to-hip ratio.
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Table 1
Weighted characteristics of Hispanic/Latino women and men from four U.S. urban centers, 2008-2011*
Women Men
No. of participants 9835 6580
Age, mean year (SE) 41.8 (0.3) 40.3 (0.3)
Hispanic background, n (%)
 Central American 1049 (7%) 683 (7%)
 Cuban 1250 (18%) 1098 (22%)
 Dominican 963 (11%) 510 (8%)
 Mexican 4022 (38%) 2450 (36%)
 Puerto Rican 1589 (15%) 1139 (17%)
 South American 635 (5%) 437 (5%)
 Others, more than one, or not reported 327 (5%) 263(4%)
Nativity (within 50 states), n (%) 1604 (21%) 1259 (25%)
Less than high school education, n (%) 3768 (33%) 2439 (32%)
Annual household income ($), n (%)
 < 20,000 4622 (46%) 2585 (38%)
 20,000-50,000 3426 (34%) 2693 (40%)
 >50,000 754 (9%) 847 (15%)
 Not reported 1033 (11%) 455 (8%)
Health insurance, n (%) 5065 (52%) 3107 (47%)
Current smoking, n (%) 1486 (16%) 1680 (27%)
Alcohol consumption, n (%)
 Not current drinker 6097 (59%) 2503 (37%)
 Low-risk drinker 3420 (37%) 3497 (54%)
 At-risk drinker † 279 (4%) 549 (9%)
Physical activity, mean MET-min/day (SE) 447 (13) 1004 (27)
Hypertension, n (%) 2691 (22%) 1784 (22%)
Diabetes, n (%) 1994 (16%) 1224 (14%)
Dyslipidemia, n (%) 5962 (59%) 3630 (52%)
Obesity measures, median (IQR)
 Body mass index, kg/m2 28.8 (25.2, 33.3) 28.3 (25.3, 31.8)
 Waist circumference, cm 95 (86, 104) 97 (88, 106)
 Waist-to-hip ratio 0.90 (0.84, 0.94) 0.94 (0.90, 0.99)
 Waist-to-height ratio 0.61 (0.55, 0.67) 0.57 (0.52, 0.62)
 Fat mass index 11.1 (8.3, 14.4) 7.7 (5.7, 10.2)
 Body fat percent, % 39 (33, 44) 27 (22, 32)
Cardiometabolic markers, median (IQR)
 Systolic blood pressure, mmHg 112 (103, 125) 121 (113, 130)
 Diastolic blood pressure, mmHg 69 (63, 77) 72 (65, 80)
 LDL-cholesterol, mg/dl 114 (93, 140) 119 (95, 144)
 HDL-cholesterol, mg/dl 50 (42, 59) 43 (37, 50)
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Women Men
 Triglycerides, mg/dl 101 (70, 147) 117 (79, 178)
 Fasting glucose, mg/dl 92 (86, 99) 96 (90, 103)
 2-h glucose, mg/dl 113 (94, 138) 105 (87, 130)
 Fasting insulin, mU/L 10.6 (6.9, 16.2) 9.9 (6.0, 15.9)
 HOMA-IR 2.5 (1.6, 4.0) 2.5 (1.5, 4.2)
 Hemoglobin A1c, % 5.4 (5.2, 5.8) 5.4 (5.2, 5.7)
*
Values (except No.) are weighted for study design and nonresponse and age standardized to Census 2010 US characteristics of the target 
population.
†
Women: ≥7 drinks/week; Men: ≥14 drinks/week. SE, standard error; MET, metabolic equivalent; IQR, interquartile range.
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Table 3
Prevalence ratios (95% confidence intervals) for hypertension, diabetes and dyslipidemia 




 BMI 1.43 (1.36, 1.51) 1.31 (1.26, 1.36) 1.17 (1.14, 1.20)
 WC 1.47 (1.40, 1.55) 1.29 (1.24, 1.34) 1.19 (1.16, 1.22)
 WHR 1.54 (1.46, 1.62) 1.17 (1.12, 1.23) 1.19 (1.16, 1.23)
 WHtR 1.49 (1.41, 1.57) 1.29 (1.24, 1.34) 1.20 (1.17, 1.22)
 %BF 1.46 (1.35, 1.59) 1.30 (1.23, 1.38) 1.20 (1.16, 1.24)
 FMI 1.41 (1.33, 1.49) 1.30 (1.25, 1.35) 1.17 (1.15, 1.20)
Men
 BMI 1.44 (1.36, 1.53) 1.36 (1.30, 1.42) 1.22 (1.19, 1.26)
 WC 1.48 (1.39, 1.57) 1.34 (1.28, 1.41) 1.24 (1.20, 1.27)
 WHR 1.53 (1.42, 1.66) 1.29 (1.22, 1.37) 1.26 (1.22, 1.30)
 WHtR 1.49 (1.40, 1.59) 1.35 (1.29, 1.42) 1.24 (1.20, 1.27)
 %BF 1.37 (1.28, 1.48) 1.36 (1.29, 1.44) 1.25 (1.21, 1.29)
 FMI 1.38 (1.30, 1.47) 1.34 (1.29, 1.40) 1.21 (1.17, 1.24)
*
Adjusted for age, sampling scheme of the Hispanic Community Health Study /Study of Latinos (HCHS/SOL), Hispanic background, field center, 
nativity, education level, health insurance status, annually household income, smoking, alcohol consumption, and physical activity.
BMI, body mass index; SD, standard deviation; WC, waist circumference; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio; %BF, percent 
body fat; FMI, fat mass index.
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